Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    S1107
Show Display Options
Rank Status Study
1 Active, not recruiting Tivantinib With or Without Erlotinib Hydrochloride in Treating Patients With Metastatic or Locally Advanced Kidney Cancer That Cannot Be Removed by Surgery
Conditions: Recurrent Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Interventions: Drug: Erlotinib Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Tivantinib

Indicates status has not been verified in more than two years